Shots:

• uniQure has an option to acquire Gen-X to identify novel synthetic promoters to be use in gene therapy products- until the expiry of research collaboration
• The companies will exclusively work together to develop promoters utilizing SuRE technology for the uniQure’s research pipeline and will explore the further development of AAV vector libraries containing fragments of the non-coding human genome
• The collaboration will combine Gen-X platform will uniQure’s expertise in AAV gene therapy which accelerates the development of advanced gene therapy candidates

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: LinkedIn